A Boxed Warning explaining the risk of medication errors involving inadvertent neuraxial administration will be added to the labeling. The Food and Drug Administration (FDA) has issued an updated ...
Along with the boxed warning, FDA will require a statement on product labeling indicating that TXA injection is contraindicated as a neuraxial injection, and have the dose and administration section ...
Clinicians must exercise extreme caution when administering the antifibrinolytic drug to prevent life-threatening mix-ups ...